Stockreport

Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial [Yahoo! Finance]

Oric Pharmaceuticals, Inc.  (ORIC) 
PDF dose after dose-optimization showed comparable exposure and pharmacodynamic target engagement to 600 mg but a higher incidence of clinically meaningful toxicities at the [Read more]